Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

19.10
-0.2150-1.11%
Post-market: 19.100.00000.00%16:27 EDT
Volume:1.16M
Turnover:22.33M
Market Cap:2.17B
PE:-7.68
High:19.56
Open:18.94
Low:18.94
Close:19.31
52wk High:30.06
52wk Low:13.41
Shares:113.58M
Float Shares:108.26M
Volume Ratio:0.82
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:4.13
PE(LYR):-7.85

Loading ...

Immunome Grants Inducement Stock Options, RSUs to 10 New Employees Under 2024 Plan

Reuters
·
Yesterday

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Yesterday

Immunome (IMNM) Gets a Hold from Stifel Nicolaus

TIPRANKS
·
Oct 06

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
Oct 06

Immunome Issues 4,425,487 Shares to Bristol-Myers Squibb in Unregistered Sale

Reuters
·
Oct 05

Immunome - Pays Bms $20 Mln Cash and Issues 4,425,487 Shares as Amendment Consideration - SEC Filing

THOMSON REUTERS
·
Oct 05

Immunome - Has no Further Payment Obligations to Bms Under License Agreement - SEC Filing

THOMSON REUTERS
·
Oct 05

Immunome - Enters Amendment No. 4 to License Agreement with Bristol-Myers Squibb Company on Oct 2, 2026 - SEC Filing

THOMSON REUTERS
·
Oct 05

Immunome - Amendment Removes Co's Milestone & Royalty Payment Obligations and Assigns Patent Rights Related to Varegacestat, Al101 - SEC Filing

THOMSON REUTERS
·
Oct 05

US Stocks on the MOVE-Cardinal Health, nVent, Acuity

Reuters
·
Oct 02

Immunome Climbs as Stifel Initiates Coverage

Reuters
·
Oct 01

Immunome Price Target Announced at $24.00/Share by Stifel

Dow Jones
·
Oct 01

Immunome, Inc. : Stifel Initiates Coverage with Hold Rating; Price Target $24

THOMSON REUTERS
·
Oct 01

Stifel Initiates Immunome at Hold With $24 Price Target

MT Newswires Live
·
Oct 01

Barclays Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Oct 01

Immunome initiated with a Hold at Stifel

TIPRANKS
·
Oct 01

Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)

TIPRANKS
·
Sep 30

Immunome announces IND clearance for IM-1340 in solid tumors

TIPRANKS
·
Sep 30

Immunome Says FDA Clears IND for IM-1340 Solid Tumor ADC

Reuters
·
Sep 30

Immunome, - to Initiate Phase 1 Study of IM-1340 in Q4 2026

THOMSON REUTERS
·
Sep 30